DYN Key Statistics, Chart & Performance
The current stock price of DYN is 17.77 USD. In the past month the price decreased by -9.75%. In the past year, price increased by 11.97%.
DYN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About DYN
Company Profile
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 240 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Company Info
DYNE THERAPEUTICS INC
1560 Trapelo Road
Waltham MASSACHUSETTS 02451 US
CEO: Joshua Brumm
Employees: 240
Phone: 17817868230
DYNE THERAPEUTICS INC / DYN FAQ
Can you describe the business of DYNE THERAPEUTICS INC?
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 240 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Can you provide the latest stock price for DYNE THERAPEUTICS INC?
The current stock price of DYN is 17.77 USD. The price decreased by -2.68% in the last trading session.
Does DYN stock pay dividends?
DYN does not pay a dividend.
What is the ChartMill technical and fundamental rating of DYN stock?
DYN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for DYN stock?
20 analysts have analysed DYN and the average price target is 39.97 USD. This implies a price increase of 124.94% is expected in the next year compared to the current price of 17.77.
Would investing in DYNE THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DYN.
DYN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DYN. When comparing the yearly performance of all stocks, DYN is one of the better performing stocks in the market, outperforming 77.89% of all stocks.
DYN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DYN. While DYN seems to be doing ok healthwise, there are quite some concerns on its profitability.
DYN Financial Highlights
Over the last trailing twelve months DYN reported a non-GAAP Earnings per Share(EPS) of -3.66. The EPS decreased by -2.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.88% | ||
| ROE | -61.26% | ||
| Debt/Equity | 0.14 |
DYN Forecast & Estimates
20 analysts have analysed DYN and the average price target is 39.97 USD. This implies a price increase of 124.94% is expected in the next year compared to the current price of 17.77.